Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Suzhou Guokuang Pharmtech Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, PHILLIP MATTHEW RZECZYCKI, who is also identified as the busiest examiner for the company. Prosecution is localized in 1 distinct art unit. With RZECZYCKI, PHILLIP MATTHEW handling 1 busiest examiner pending action, the company's immediate legal focus is limited to a single reviewer.
This lack of examiner diversity means that the progress of the portfolio is tied to the specific habits of one individual. Practitioners should be aware that with only 1 distinct art unit involved, there are no other concurrent applications to provide context on departmental trends. The presence of 1 pending office action indicates a streamlined prosecution profile at this time.
Because the 1 distinct examiner and 1 distinct art unit represent the whole of the pending workload, the strategy must be highly tailored to the Biotechnology & Pharmaceuticals sector's specific requirements. Aligning with the expectations of PHILLIP MATTHEW RZECZYCKI is essential for moving this single pending office action toward allowance. This centralized approach simplifies the management of the portfolio but increases the impact of a single examiner's discretion.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282419 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18282419 | CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §112 | Final Rejection | — | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSuzhou Guokuang Pharmtech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Phillip Matthew Rzeczycki has the most, with 1 of Suzhou Guokuang Pharmtech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
